Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 278, Issue -, Pages 277-279Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.11.017
Keywords
Escalation therapy; Immunosuppression; Multi-drug resistance transporter; Pharmacogenetics
Categories
Funding
- German Bundesministerium fur Bildung und Forschung (BMBF), German competence Network Multiple Sclerosis (KKNMS) [01GI0914]
- Bayer Healthcare
- Biogen Idec
- Merck Serono
- Teva Neuroscience
- Johnson Johnson
- Teva
- Bayer
- Novartis
- Bayer Schering
- German Ministry for Education and Research [BMBF, 'German Competence Network Multiple Sclerosis' (KKNMS)] [01GI0914]
Ask authors/readers for more resources
Background: Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS).ABC-transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective: To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods: 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes. Results: 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no association between genotype and treatment response. Conclusion: Our data discourages the use of mitoxantrone in PPMS regardless of pharmacogenetic response markers previously described in RP/SPMS. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available